AOD9604's features are what set it apart from its parent compound and other fat-loss agents. Its mechanism, while not fully elucidated in human clinical trials, is theorized to be unique.
●Targeted Metabolic Action: Unlike HGH, which has a broad spectrum of effects, AOD9604 is believed to act specifically on adipocytes (fat cells). It is thought to mimic the way the body naturally stimulates fat breakdown, potentially by binding to a specific fat cell receptor site.
●Dual-Action Theory: Research indicates a potential two-pronged approach:
1.Stimulation of Lipolysis: It may enhance the enzymatic process that breaks down stored triglycerides into free fatty acids, making them available for energy production.
2.Inhibition of Lipogenesis: Concurrently, it may block the action of enzymes and pathways responsible for converting carbohydrates and sugars into new fat stores.
●Absence of Growth Promotion: A critical feature is its hypothesized dissociation from the growth-promoting effects of HGH. It does not significantly elevate IGF-1 levels, which theoretically eliminates the associated risks of acromegaly (bone overgrowth) or organ enlargement.
●Potential for Improved Insulin Sensitivity: Some preliminary studies suggest it may improve glucose tolerance and insulin sensitivity, a stark contrast to full-length HGH, which can be diabetogenic. This makes it a compound of interest for metabolic syndrome research.
